Bicyclic protein kinase inhibitors
    25.
    发明授权
    Bicyclic protein kinase inhibitors 失效
    双环蛋白激酶抑制剂

    公开(公告)号:US07189721B2

    公开(公告)日:2007-03-13

    申请号:US10725267

    申请日:2003-12-02

    CPC分类号: C07D471/04 C07D209/34

    摘要: The present invention relates to novel 3-hetero-arylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

    摘要翻译: 本发明涉及调节蛋白激酶活性的新型3-异亚烷基-2-二氢吲哚酮化合物及其生理上可接受的盐,因此预期可用于预防和治疗蛋白激酶相关的细胞病症例如癌症。

    Tyrosine kinase inhibitors
    29.
    发明授权
    Tyrosine kinase inhibitors 失效
    酪氨酸激酶抑制剂

    公开(公告)号:US06987113B2

    公开(公告)日:2006-01-17

    申请号:US09096014

    申请日:1998-06-10

    CPC分类号: C07D209/34

    摘要: The present invention relates to novel 3-hetero-arylideneazaindolin-2-one compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.

    摘要翻译: 本发明涉及预期调节蛋白酪氨酸激酶活性的新型3-杂芳基亚氨基二氢吡喃-2-酮化合物及其生理上可接受的盐和前药,因此可用于预防和治疗蛋白质酪氨酸激酶相关细胞 疾病如癌症。

    Azaindole tyrosine kinase inhibitors
    30.
    发明授权
    Azaindole tyrosine kinase inhibitors 失效
    阿魏酸酪氨酸激酶抑制剂

    公开(公告)号:US06849641B1

    公开(公告)日:2005-02-01

    申请号:US09191199

    申请日:1998-11-12

    CPC分类号: C07D209/34

    摘要: The present invention relates to novel 3-hetero-arylideneazaindolin-2-one compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.

    摘要翻译: 本发明涉及预期调节蛋白酪氨酸激酶活性的新型3-杂芳基亚氨基二氢吡喃-2-酮化合物及其生理上可接受的盐和前药,因此可用于预防和治疗蛋白质酪氨酸激酶相关细胞 疾病如癌症。